LAS VEGAS, June 16, 2017 /PRNewswire/ -- GB Sciences, Inc. (GBLX)
On June 15, 2017, LSU announced that GB Sciences has been selected as the winning bidder for LSU Solicitation - SFO 0000000165 for the cultivation, production and use of medical marijuana. The awarding of the final contract is contingent upon:
- Securing of a Louisiana based financial institution
- Final approval by the Louisiana State Board of Supervisors
To read the announcement, follow this link:
About Louisiana State University
Louisiana State University and Agricultural and Mechanical College (hereinafter referred as the "University" or "LSU") is the state's comprehensive research university. The University is classified by the Carnegie Foundation as a Doctorate-granting university with very high research activity – one of the only 27 public and 23 private universities in the nation. The University's instructional programs include 194 undergraduate and graduate/professional degrees. The University is accredited by the Commission on Colleges of the Southern Association of Colleges and Schools (SACSCOC) to award bachelors, masters, doctoral, and professional degrees.
As the premier university of the state, the mission of the University is the generation, preservation, dissemination, and application of knowledge and the cultivation of the arts for the benefit of the peoples of the state, the nation, and the global community. The University offers challenging undergraduate, graduate, doctoral, and professional education programs for outstanding students from Louisiana, the nation, and other countries. The University's libraries and museums preserve the rich cultural heritage of the state, and scholar and artists at the University contribute to the literature, history, science, technology, and arts of our culturally diverse community.
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://growblox.com
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gb-sciences-announced-as-lsu-bid-winner-300475340.html